Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Oxyntomodulin (endogenous GLP-1R/GCGR Dual)

MARKETED

GLP-1/glucagon dual agonist

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

Oxyntomodulin (endogenous GLP-1R/GCGR Dual) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Oxyntomodulin (endogenous GLP-1R/GCGR Dual) MARKETED
Appetite and food intake Decrease
Moderate evidence

Intravenous oxyntomodulin reduced ad libitum energy intake at a buffet meal by ~19.3% and cumulative 12-h energy intake by ~11.3% in healthy normal-weight humans, with...

Cohen MA et al. (Bloom group), J Clin Endocrinol Metab 2003;88(10):4696-4701 Source
Full findingIntravenous oxyntomodulin reduced ad libitum energy intake at a buffet meal by ~19.3% and cumulative 12-h energy intake by ~11.3% in healthy normal-weight humans, with reduced hunger, no nausea, no change in food palatability, and suppressed preprandial ghrelin. Combination (GLP-1R+GCGR) intake reduction; the glucagon-arm contribution cannot be isolated from this datum.
PopulationHealthy normal-weight humans
Fundingacademic - UK Medical Research Council and Wellcome Trust
Scope limitsReused from corpus T9-GCGR-05. Combination-only; per-receptor split not possible. Mechanistic contrast (Baggio 2004) indicates the satiety is GLP-1R-driven — not a positive GCGR satiety attribution.
Comparatorssaline